ASPARTATE PLATELET RATIO INDEX AS A PREDICTOR OF SEVERITY OF FIBROSIS IN CHRONIC HEPATITS C
DOI:
https://doi.org/10.22159/ajpcr.2023.v16i4.47535Keywords:
aspartate platelet ratio index, chronic liver disease, chronic hepatitis C, cirrhosis, predictor indexAbstract
Objectives: Hepatitis C is an important emerging cause for chronic liver disease in India, with high risk for chronicity and hepatocellular carcinoma. Chronic hepatitis C (CHC) is the most common cause for chronic liver disease and cirrhosis, and liver transplantation. Liver biopsy is the gold standard for evaluation of fibrosis - however it remains fraught with drawbacks and limitations. The aspartate aminotransferase-to-platelet ratio index (APRI), a tool with limited expense and widespread availability is a promising non-invasive alternative to liver biopsy for detecting hepatic fibrosis in CHC.(1) The objectives of the study were to determine the association between APRI and severity of fibrosis in Hepatitis C (2) and to describe the clinical profile of patients with Hepatitis C.
Methods: A cross-sectional descriptive study in 60 patients diagnosed with hepatitis C for more than 6 months admitted to the General Medicine and Medical Gastroenterology Departments of Govt Medical College, Kottayam. Data were collected with a structured pro forma and analyzed using SPSS.
Results: 35 of 60 patients belonged to METAVIR F3 (severe fibrosis) and F4 (cirrhosis). An APRI of 0.5 was associated with a finding of F3 or F4 with a sensitivity of 97.14% and a specificity of 88%. 31 of the 60 patients belonged to F4. An APRI of 1.5 or more was a predictor for cirrhosis with a sensitivity of 93.1% and specificity of 96.77%. The positive predictive value of cirrhosis APRI threshold >1.5 is 96.4%.
Downloads
References
Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62. doi: 10.1126/ science.2523562, PMID 2523562
Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-67. doi: 10.1016/S1473- 3099(05)70216-4, PMID 16122679
Morozov VA, Lagaye S. Hepatitis C virus: Morphogenesis, infection and therapy. World J Hepatol 2018;10:186-212. doi: 10.4254/wjh.v10. i2.186, PMID 29527256
Li HC, Lo SY. Hepatitis C virus: Virology, diagnosis and treatment. World J Hepatol 2015;7:1377-89. doi: 10.4254/wjh.v7.i10.1377, PMID 26052383
Mukhopadhyaya A. Hepatitis C in India. J Biosci 2008;33:465-73. doi: 10.1007/s12038-008-0065-0, PMID 19208972
Dec. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 2002;123:2082-99. doi: 10.1053/gast.2002.1232082, PMID 12454863
Catanese MT, Uryu K, Kopp M, Edwards TJ, Andrus L, Rice WJ, et al. Ultrastructural analysis of hepatitis C virus particles. Proc Natl Acad Sci U S A 2013;110:9505-10. doi: 10.1073/pnas.1307527110, PMID 23690609
Gu M, Rice CM. Structures of hepatitis C virus nonstructural proteins required for replicase assembly and function. Curr Opin Virol 2013;3:129-36. doi: 10.1016/j.coviro.2013.03.013, PMID 23601958
De Francesco R, Tomei L, Altamura S, Summa V, Migliaccio G. Approaching a new era for hepatitis C virus therapy: Inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res 2003;58:1-16. doi: 10.1016/s0166- 3542(03)00028-7, PMID 12719002
Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52. doi: 10.7150/ijms.3.47, PMID 16614742
Moosavy SH, Davoodian P, Nazarnezhad MA, Nejatizaheh A, Eftekhar E, Mahboobi H. Epidemiology, transmission, diagnosis, and outcome of hepatitis C virus infection. Electron Phys 2017;9:5646-56. doi: 10.19082/5646, PMID 29238510
Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies. J Viral Hepat 2006;13:34-41. doi: 10.1111/j.1365-2893.2005.00651.x, PMID 16364080
Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012;26:401-12. doi: 10.1016/j.bpg.2012.09.009, PMID 23199500
Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepatitis C virus: Systematic review and meta-analysis. Clin Infect Dis 2014;59:765-73. doi: 10.1093/cid/ciu447, PMID 24928290
Kiyosawa K, Sodeyama T, Tanaka E, Nakano Y, Furuta S, Nishioka K, et al. Hepatitis C in hospital employees with needle-stick injuries. Ann Intern Med 1991;115:367-9. doi: 10.7326/0003-4819-115-5-367, PMID 1907441
Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001;194:1395-406. doi: 10.1084/jem.194.10.1395, PMID 11714747
Farci P, Alter HJ, Shimoda A, Govindarajan S, Cheung LC, Melpolder JC, et al. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med 1996;335:631-4. doi: 10.1056/ NEJM199608293350904, PMID 8687517
Khatun M, Ray RB. Mechanisms underlying hepatitis C virus-associated hepatic fibrosis. Cells 2019;8:1249. doi: 10.3390/cells8101249, PMID 31615075
Lieber CS. Alcohol and hepatitis C. Alcohol Res Health 2001;25:245-54. PMID 11910701
Rosman AS, Waraich A, Galvin K, Casiano J, Paronetto F, Lieber CS. Alcoholism is associated with hepatitis C but not hepatitis B in an urban population. Am J Gastroenterol 1996;91:498-505. PMID 8633498
Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32. doi: 10.1016/s0140-6736(96)07642-8, PMID 9121257
Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001;183:1112-5. doi: 10.1086/319273, PMID 11237838
Doyle JS, Hellard ME, Thompson AJ. The role of viral and host genetics in natural history and treatment of chronic HCV infection. Best Pract Res Clin Gastroenterol 2012;26:413-27. doi: 10.1016/j. bpg.2012.09.004, PMID 23199501
Parigi TL, Torres MC, Aghemo A. Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure. Clin Mol Hepatol 2019;25:360-5. doi: 10.3350/cmh.2019.0022, PMID 31042864
Asselah T, Marcellin P, Bedossa P. Improving performance of liver biopsy in fibrosis assessment. J Hepatol 2014;61:193-5. doi: 10.1016/j. jhep.2014.03.006, PMID 24650692
Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344:495-500. doi: 10.1056/NEJM200102153440706, PMID 11172192
Klein MA. Diagnostic liver pathology. In: Lee RG, editor. Hepatology. St. Louis: Mosby; 1994. p. 115. Available from: https://aasldpubs. onlinelibrary.wiley.com/doi/abs/10.1002/hep.1840200644 [Last accessed on 2020 Nov 14].
Piccinino F, Sagnelli E, Pasquale G, Giusti G, Battocchia A, Bernardi M. Complications following percutaneous liver biopsy: A multicentre retrospective study on 68 276 biopsies. J Hepatol 1986;2:165-73. doi: 10.1016/s0168-8278(86)80075-7, PMID 3958472
Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med 1993;118:96-8. doi: 10.7326/0003-4819-118-2-199301150-00003, PMID 8416324
Castéra L, Nègre I, Samii K, Buffet C. Pain experienced during percutaneous liver biopsy. Hepatology 1999;30:1529-30. doi: 10.1002/ hep.510300624, PMID 10610352
Perrillo RP. The role of liver biopsy in hepatitis C. Hepatology 1997;26:57S-61. doi: 10.1002/hep.510260710, PMID 9305665
Van Thiel DH, Gavaler JS, Wright H, Tzakis A. Its safety and complications as seen at a liver transplant center. Transplantation 1993;55:1087-9.
Raines DR, Van Heertum RL, Johnson LF. Intrahepatic hematoma: A complication of percutaneous liver biopsy. Gastroenterology 1974;67:284-9. doi: 10.1016/S0016-5085(19)32892-6, PMID 4277076
Lichtenstein DR, Kim D, Chopra S. Delayed massive hemobilia following percutaneous liver biopsy: Treatment by embolotherapy. Am J Gastroenterol 1992;87:1833-8.
Ruben RA, Chopra S. Bile peritonitis after liver biopsy: Nonsurgical management of a patient with an acute abdomen: A case report with review of the literature. Am J Gastroenterol 1987;82:265-8. PMID 3548330
Hanafee W, Weiner M. Transjugular percutaneous cholangiography. Radiology 1967;88:35-9. doi: 10.1148/88.1.35, PMID 6015615
McAfee JH, Keeffe EB, Lee RG, Rösch J. Transjugular liver biopsy. Hepatology 1992;15:726-32. Doi: 10.1002/hep.1840150429
Lundquist A. Fine-needle aspiration biopsy of the liver. Applications in clinical diagnosis and investigation. Acta Med Scand Suppl 1971;520:1-28. PMID 5287096
De Lucca Schiavon L, Narciso-Schiavon JL, de Carvalho-Filho RJ. Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. World J Gastroenterol 2014;20:2854-66. doi: 10.3748/wjg.v20.i11.2854, PMID 24659877
Giannini E, Botta F, Fasoli A, Ceppa P, Risso D, Lantieri PB, et al. Progressive liver functional impairment is associated with an increase in AST/ALT ratio. Dig Dis Sci 1999;44:1249-53. doi: 10.1023/a:1026609231094, PMID 10389705
Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003;163:218-24. doi: 10.1001/archinte.163.2.218, PMID 12546613
Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin- Venier V, et al. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007;46:32-6. doi: 10.1002/hep.21669, PMID 17567829
Forns X, Ampurdanès S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36:986-92. doi: 10.1053/jhep.2002.36128, PMID 12297848
Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-26. doi: 10.1053/jhep.2003.50346, PMID 12883497
Qamar AA, Grace ND, Groszmann RJ, Garcia-Tsao G, Bosch J, Burroughs AK, et al. Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol 2009;7:689-95. doi: 10.1016/j.cgh.2009.02.021, PMID 19281860
Mitchell O, Feldman DM, Diakow M, Sigal SH. The pathophysiology of thrombocytopenia in chronic liver disease. Hepat Med 2016;8:39-50. doi: 10.2147/HMER.S74612, PMID 27186144
Kawasaki T, Takeshita A, Souda K, Kobayashi Y, Kikuyama M, Suzuki F, et al. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. Am J Gastroenterol 1999;94:1918-22. doi: 10.1111/j.1572-0241.1999.01231.x, PMID 10406260
Zeldis JB, Mugishima H, Steinberg HN, Nir E, Gale RP. In vitro hepatitis B virus infection of human bone marrow cells. J Clin Invest 1986;78:411-7. PMC423568
Strong Association of Hepatitis C Virus (HCV) Infection and Thrombocytopenia: Implications from a Survey of a Community with Hyperendemic HCV Infection Clinical Infectious Diseases. Oxford Academic. Available from: https://www.academic.oup.com/cid/ article/39/6/790/357870 [Last accessed on 2020 Nov 15].
García-Suárez J, Burgaleta C, Hernanz N, Albarran F, Tobaruela P, Alvarez-Mon M. HCV-associated thrombocytopenia: Clinical characteristics and platelet response after recombinant alpha2b-interferon therapy. Br J Haematol 2000;110:98-103. doi: 10.1046/j.1365- 2141.2000.02132.x, PMID 10930984
Jandl JH, Aster RH, Forkner CE, Fisher AM, Vilter RW. Splenic pooling and the pathophysiology of hypersplenism. Trans Am Clin Climatol Assoc 1967;78:9-27. PMID 5339085
Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, Marchant RE. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 1996;88:2939-50. doi: 10.1182/blood.V88.8.2939.bloodjournal8882939, PMID 8874190
Lian EC. Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond. Semin Thromb Hemost 2005;31:625-32. doi: 10.1055/s-2005-925468, PMID 16388413
Ruggeri ZM. Mechanisms of shear-induced platelet adhesion and aggregation. Thromb Haemost 1993;70:119-23. doi: 10.1055/s-0038- 1646171, PMID 8236086
Uemura M, Fujimura Y, Matsumoto M, Ishizashi H, Kato S, Matsuyama T, et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 2008;99:1019-29. doi: 10.1160/ TH08-01-0006, PMID 18521503
Uemura M, Fujimura Y, Ko S, Matsumoto M, Nakajima Y, Fukui H. Pivotal role of ADAMTS13 function in liver diseases. Int J Hematol 2010;91:20-9. doi: 10.1007/s12185-009-0481-4, PMID 20054668
Oda A, Miyakawa Y, Druker BJ, Ozaki K, Yabusaki K, Shirasawa Y, et al. Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. Blood 1996;87:4664-70. doi: 10.1182/blood.V87.11.4664.bloodjournal87114664, PMID 8639835
Pereira J, Accatino L, Alfaro J, Brahm J, Hidalgo P, Mezzano D. Platelet autoantibodies in patients with chronic liver disease. Am J Hematol 1995;50:173-8. doi: 10.1002/ajh.28
Pawlotsky JM, Bouvier M, Fromont P, Deforges L, Duval J, Dhumeaux D, et al. Hepatitis C virus infection and autoimmune thrombocytopenic purpura. J Hepatol 1995;23:635-9. PMID: 8750160
Chiao EY, Engels EA, Kramer JR, Pietz K, Henderson L, Giordano TP,et al. Risk of immune thrombocytopenic purpura and autoimmune hemolytic anemia among 120 908 US veterans with hepatitis C virus infection. Arch Intern Med 2009;169:357-63. doi: 10.1001/ archinternmed.2008.576, PMID 19237719
Bordin G, Ballaré M, Zigrossi P, Bertoncelli MC, Paccagnino L, Baroli A, et al. A laboratory and thrombokinetic study of HCV-associated thrombocytopenia: A direct role of HCV in bone marrow exhaustion? Clin Exp Rheumatol 1995;13:S39-43. PMID 8730475
Hamaia S, Li C, Allain JP. The dynamics of hepatitis C virus binding to platelets and 2 mononuclear cell lines. Blood 2001;98:2293-300. doi: 10.1182/blood.v98.8.2293, PMID 11588022
Dahal S, Upadhyay S, Banjade R, Dhakal P, Khanal N, Bhatt VR. Thrombocytopenia in patients with chronic hepatitis C virus infection. Mediterr J Hematol Infect Dis 2017;9:e2017019. doi: 10.4084/ MJHID.2017.019, PMID 28293407
Lijnen HR, Collen D. Mechanisms of physiological fibrinolysis. Baillieres Clin Haematol 1995;8:277-90. PMID: 7549063.
Stein SF, Harker LA. Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis. J Lab Clin Med 1982;99:217-30. PMID 7061918
Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology 1988;8:232-6. doi: 10.1002/ hep.1840080207, PMID 3281884
Vroon DH, Israili Z. Aminotransferases. In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd ed. Boston: Butterworths; 1990.
Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC, Public Policy Committee of the American Association for the Study of Liver Disease. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 2008;47:1363-70. doi: 10.1002/hep.22109, PMID 18366115
Adams DH. Sleisenger and Fordtran’s gastrointestinal and liver disease. Gut 2007;56:1175. doi: 10.1136/gut.2007.121533
Jung KS, Kim SU. Clinical applications of transient elastography. Clin Mol Hepatol 2012;18:163-73. doi: 10.3350/cmh.2012.18.2.163,PMID 22893866
Yeh WC, Li PC, Jeng YM, Hsu HC, Kuo PL, Li ML, et al. Elastic modulus measurements of human liver and correlation with pathology. Ultrasound Med Biol 2002;28:467-74. doi: 10.1016/s0301- 5629(02)00489-1, PMID 12049960
Miranda-Pettersen K, Morais-de-Jesus M, Daltro-Oliveira R, Dias AD, Teles C, Schinoni MI, et al. The fatigue impact scale for daily use in patients with hepatitis B virus and hepatitis C virus chronic infections. Ann Hepatol 2015;14:310-6. doi: 10.1016/S1665-2681(19)31269-4, PMID 25864210
Viana MS, Takei K, Yamaguti DC, Guz B, Strauss E. Use of AST platelet ratio index (APRI Score) as an alternative to liver biopsy for treatment indication in chronic hepatitis C. Ann Hepatol 2009;8:26-31.
Papadopoulos N, Vasileiadi S, Papavdi M, Sveroni E, Antonakaki P, Dellaporta E, et al. Liver fibrosis staging with combination of APRI and FIB-4 scoring systems in chronic hepatitis C as an alternative to transient elastography. Ann Gastroenterol 2019;32:498-503. doi: 10.20524/aog.2019.0406, PMID 31474797
Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cárdenas E, Sánchez- Avila F, Vargas-Vorácková F. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol 2008;7:350-7.
Taneja S, Tohra S, Duseja A, Dhiman RK, Chawla YK. Noninvasive assessment of liver fibrosis by transient elastography and FIB4/APRI for prediction of treatment response in chronic hepatitis C-an experience from a tertiary Care Hospital. J Clin Exp Hepatol 2016;6:282-90. doi: 10.1016/j.jceh.2016.08.001, PMID 28003717
Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-50. doi: 10.1053/j.gastro.2004.11.018, PMID 15685546
Mendes LC, Ferreira PA, Miotto N, Zanaga L, Gonçales E, Lazarini MS, et al. Transient elastography and APRI score: Looking at false positives and false negatives. Diagnostic performance and association to fibrosis staging in chronic hepatitis C. Braz J Med Biol Res 2016;49:e5432. doi: 10.1590/1414-431X20165432, PMID 27533769
Published
How to Cite
Issue
Section
Copyright (c) 2023 Sue Ann Zachariah
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
